|
Adult Gliosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Coamplification of CDK4 and MDM2 was detected in one gliosarcoma.
|
10666371 |
2000 |
|
Adult Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that protease-resistant galectin-9, hG9NC(null), but not galectin-1 or -8, prevented cell growth of malignant B cells, such as Burkitt lymphoma (BL) and Hodgkin lymphoma (HL). beta-galactoside binding was essential for galectin-9-induced cell growth suppression. hG9NC(null) induced cell cycle arrest by reducing the expression of cyclin D1, D2, B1, Cdk4, Cdc25C and c-Myc, and apoptosis by reducing the expression of XIAP, c-IAP2 and survivin.
|
18503581 |
2008 |
|
Adult Liposarcoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma.
|
19626636 |
2009 |
|
Adult Liposarcoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
|
17214366 |
2007 |
|
Adult Liposarcoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature.
|
31798393 |
2019 |
|
Adult Liposarcoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
We demonstrate that an alteration in the CDKN2A/CDKN2B/CDK4/CCND1 pathway is present in almost all cases without CDK4 amplification, thereby confirming the pivotal role of this pathway in liposarcoma oncogenesis.
|
21910158 |
2011 |
|
Adult Liposarcoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
However, these profiles did not segregate by histology (lung adenocarcinoma-appendiceal cancer (KRAS G12D and GNAS R201C), and lung adenocarcinoma-liposarcoma (CDK4 and MDM2 amplification pairs)).
|
26418953 |
2015 |
|
Adult Liposarcoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
As well as confirming the synergistic effect of MDM2 and CDK4, these results are consistent with the concept that amplicon(s) excluding MDM2 may contribute to transformation and support a role of CDK4 in opposing p53 function, particularly in NR WD liposarcoma.
|
9713346 |
1998 |
|
Adult Liposarcoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
CDK4/6 inhibitors have antiproliferative activity in CDK4-amplified liposarcoma and neuroblastoma, suggesting CDK4/6 inhibition as a potential therapeutic strategy in fusion-positive RMS.
|
25810375 |
2015 |
|
Adult Lymphoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
As drug resistance remains a major challenge and CDK4 and PI3K are dysregulated at a high frequency in human cancers, targeting CDK4 in genome-based combination therapy represents a novel approach to lymphoma and cancer therapy.
|
25082755 |
2014 |
|
Adult Lymphoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Furthermore, our data suggest that targeting CDK4 may increase the risk for the development and/or progression of lymphoma.
|
24614102 |
2014 |
|
Adult Lymphoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.
|
8628020 |
1996 |
|
Adult Lymphoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
To compare the expression status of G1 cyclins, these EBV-associated lymphoma lines (6 EBV[-] human SCID mouse lymphoma lines, 13 human B cell lymphomas and 8 samples of human tonsil tissue) were examined by reverse transcription-polymerase chain reaction-Southern blotting, Western blotting and immunohistochemistry. mRNA expression of cyclin D1 (CCND1), cyclin D2 (CCND2), cyclin E (CCNE), cyclin-dependent kinase 2 (CDK2) and 4 (CDK4) was found in all 3 types of lymphomas.
|
11291051 |
2001 |
|
Adult Lymphoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Statistical analysis of the expression data revealed the combination of CCND1 and CDK4 as the best classifier concerning separation of both lymphoma types.
|
12036888 |
2002 |
|
Adult Lymphoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The mRNA and protein expression levels of B cell leukemia/lymphoma (Bcl‑2), Bcl‑2 associated X (Bax), cyclin dependent kinase 4 (CDK4), cyclin D1 and p21 were evaluated using reverse transcription‑polymerase chain reaction and western blot analysis, respectively.
|
29115462 |
2018 |
|
Adult Lymphoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.
|
9031081 |
1996 |
|
Adult Lymphoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
In the present study, we analysed 34 de novo diffuse large B cell lymphoma (DLCL) from a population-based lymphoma registry for alterations of the RB1 pathway at the genetic (RB1 and CDK4) and protein (pRb, cyclin D1, cyclin D3, CDK4, and E2F-1) level.
|
10803523 |
2000 |
|
Adult Malignant Peripheral Nerve Sheath Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor.
|
21325289 |
2011 |
|
Adult Medulloblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The CDK 4/6 inhibitor palbociclib decreased proliferation, increased apoptosis, and significantly extended the survival of mice with orthotopic medulloblastoma xenografts.
|
27012813 |
2016 |
|
Adult Medulloblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The drug caused rapid regression of Sonic hedgehog (SHH) and <i>MYC</i>-amplified group 3 medulloblastoma subcutaneous tumors and provided a highly significant survival advantage to mice bearing <i>MYC</i>-amplified intracranial tumors.<b>Conclusions:</b> Inhibition of CDK4/6 is potentially a highly effective strategy for the treatment of SHH and <i>MYC</i>-amplified group 3 medulloblastoma.<i></i>.
|
28637687 |
2017 |
|
Adult Rhabdomyosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CDK4/6 inhibitors have antiproliferative activity in CDK4-amplified liposarcoma and neuroblastoma, suggesting CDK4/6 inhibition as a potential therapeutic strategy in fusion-positive RMS.
|
25810375 |
2015 |
|
Adult Rhabdomyosarcoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Among LMS and RMS most cases with CDK4, MDM2 and GLI gene alterations also showed a simultaneous high expression of the relative protein.
|
15024701 |
2004 |
|
Adult Rhabdomyosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
An osteosarcoma cell line, OsACL, manifested a 25-fold increased copy number of CDK4, amplified concordantly with both GLI and MDM2, whereas a rhabdomyosarcoma cell line, SJRH30, was found to have an amplicon that included CDK4 and GLI but not MDM2.
|
8221695 |
1993 |
|
Adult Soft Tissue Sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results suggest that: (a) alteration of the p16 gene is infrequent in primary soft-tissue sarcoma; (b) Cdk4 may act as an oncogene in soft-tissue sarcoma; and (c) elevated p16 and RB levels might be the result of compensatory up-regulation of these proteins to counteract CDK4 overexpression in these tumors.
|
9563903 |
1998 |
|
Adult Soft Tissue Sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gene silencing of <i>CIC-DUX4</i> as well as <i>Ccnd2, Ret</i>, and <i>Bcl2</i> effectively inhibited CDS tumor growth <i>in vitro</i> The CDK4/6 inhibitor palbociclib and the soft tissue sarcoma drug trabectedin also blocked the growth of mouse CDS.
|
28404587 |
2017 |